anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cerebral palsy (CP) is a permanent developmental disorder that occurs as a result of a lesion in the developing baby's brain. Due to the symptoms seen in CP, the individual's participation in daily living activities (ADL) is restricted and functional mobility is affected. Hippotherapy is preferred in children with CP because it includes fun activities and is effective in terms of the child's participation and motivation. The aim of this study is to examine the effect of hippotherapy on upper extremity function. In this study planned as a multicenter study, children with CP are divided into 2 groups as the study and control groups. After a 2-month application, children with CP will be evaluated in terms of upper extremity functionality and postural control. The "Statistical Package for Social Sciences (SPSS) Statistics 23.0 (SPSS Inc, Chicago, USA) program will be used in the analysis of the study data. The change in numerical variables over time in the treatment and control groups and the group-time interaction will be examined with "two-way repeated measures variance analysis". The "Chi-Square Test" will be used to examine the relationship between categorical variables. The relationship between numerical variables will be examined with the "Spearman rho correlation coefficient". The probability of error will be accepted as (p\<0.05).
After an observation period of \~5 weeks, participants receive 10 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
Tumor neovascularization is essential for the growth, invasion, and metastasis of tumors. Recent studies have highlighted the significant role of N6-methyladenosine (m6A) modification in regulating these processes. This review explores the mechanisms by which m6A influences tumor neovascularization, focusing on its impact on angiogenesis and vasculogenic mimicry (VM). We discuss the roles of m6A writers, erasers, and readers in modulating the stability and translation of angiogenic factors like vascular endothelial growth factor (VEGF), and their involvement in key signaling pathways such as PI3K/AKT, MAPK, and Hippo. Additionally, we outline the role of m6A in vascular-immune crosstalk. Finally, we discuss the current development of m6A inhibitors and their potential applications, along with the contribution of m6A to anti-angiogenic therapy resistance. Highlighting the therapeutic potential of targeting m6A regulators, this review provides novel insights into anti-angiogenic strategies and underscores the need for further research to fully exploit m6A modulation in cancer treatment. By understanding the intricate role of m6A in tumor neovascularization, we can develop more effective therapeutic approaches to inhibit tumor growth and overcome treatment resistance. Targeting m6A offers a novel approach to interfere with the tumor's ability to manipulate its microenvironment, enhancing the efficacy of existing treatments and providing new avenues for combating cancer progression.
Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I) will be provided on an online digital platform called Sleepio (BigHealth Ltd). Sleepio delivers fully automated CBT-I through 6 sessions, lasting an average of 20 minutes each, over the course of 6 weeks.
New anti-obesity medications (AOMs) have received widespread acclaim in medical journals and the media, but they also raise critical ethical, public health, and public policy concerns that have largely been ignored. AOMs are very costly, need to be taken by a patient in perpetuity (since significant rebound weight gain otherwise occurs), and threaten to shift resources and focus away from other crucial efforts at obesity treatment and prevention. Many people may feel less motivated to exercise or reduce their caloric consumption, if they assume that obesity is now medically treatable. Policy-makers may similarly come to feel that the solution to the obesity pandemic is simply to prescribe medications and that prevention efforts are far less necessary. These drugs raise concerns about justice (since AOMs will disproportionately benefit the wealthy), medicalization, and marketing. Policy-makers, clinicians, and others need to engage in multipronged educational and policy efforts to address these challenges.
A method of and system for manufacturing a nail appliqué. A liquid nail enamel having high viscosity is provided and heated to at least 100 ~F. A layer of adhesive material is applied onto a substrate, and at least a first layer of the heated liquid nail enamel is applied atop the layer of adhesive material.  Multiple layers of nail enamel may be employed, optionally having particulate matter such as glitter or mica, optionally one or more of the layers being a clear coat layer. Heaters are employed between layer depositing stations to dry the previous layer at least partially before applying the next layer.  Additionally, multiple formulations of liquid nail enamel, of differing color and/or viscosity, may be passively mixed to form an interesting striped or swirled pattern.
Arm A participants will receive a full dose of CYB004 in 2 of 2 medicine sessions, approximately three weeks apart. All participants will receive supportive EMBARK psychotherapy throughout the study.
The investigators will enroll and perform whole exome sequencing on two cohorts of patients. One cohort will consist of two hundred newborns with no known conditions whose parents will be recruited during the mother's pregnancy. The second cohort will include two hundred infants and children up to the age of five years with diagnosed conditions including conditions detected through standard newborn screening such as phenylketonuria and other inborn errors of metabolism, hearing loss and other rare conditions that may fit criteria for newborn screening in the future.

Parents will be introduced to the study by their clinician or a study recruiter. Those who agree to enroll in Phase I will review an online decision guide and be offered a study visit conducted by a genetic counselor to obtain informed consent for genomic sequencing of their child. Parents consenting to have their child's genome sequenced will be seen after the child's birth or at a convenient pre-arranged time and duplicate saliva samples will be collected from the children and one sample will be sent to the BioSpecimen Processing (BSP) Facility and to Dr. Jonathan Berg's laboratory for sequencing and the other sent to the Molecular Genetics Laboratory (MGL) for DNA extraction and storage until needed for clinical confirmation. Results will be returned for diagnostic (in the Diagnosed cohort) and medically actionable disorders of childhood (both cohorts). Two-thirds of parents who consent to sequencing will be randomly assigned to be eligible to request additional findings and use a supplement of the online decision aid. All results will be reported to parents by trained genetic professionals (genetic counselors and clinical geneticists)
OBJECTIVE: To evaluate effects of 7 days oral antibiotic prophylaxis versus no antibiotics in the patients with DJ stents after 3 days iv antibiotic on discharge with respect to urinary tract infection and stent related symptoms.
MATERIAL AND METHODS: A prospective randomized study in 90 patients being stented post PCNL/URSL. Group A: no oral antibiotics was given at the time of discharge, Group B: 7 days of oral antibiotic was given at the time of discharge. Patients were followed up and outcomes were assessed in the form of lower urinary symptoms (LUTS), urine culture and sensitivity at 1 and 3 weeks and DJ stent culture and sensitivity on removal at 3 weeks.
RESULTS: There was no significant difference in age, gender, type of surgery (PCNL/URSL), duration of DJ stent between the two groups. Patients in group A and Group B have comparable UTI and stent related symptoms at 1 and 3 weeks respectively (p = 0.95 and p = 0.916 respectively). Similarly, there were no marked difference in urine culture at 1 and 3 weeks, respectively between two groups (p = 0.71 and p = 0.63, respectively). Overall there were no significant differences in Urinary symptoms, urine culture/sensitivity at 1 and 3 weeks and also DJ stent culture and sensitivity on removal at 3 weeks between the two groups.
CONCLUSION: The incidence of UTI and stent related symptoms are same in both the groups. Therefore, prescribing oral antibiotics on discharge in selected patient with DJ stent has no added benefit and should be avoided.
For the experimental intervention, Play2Sleep consists of video-recording the mother and father separately while engaged in a structured play session. Immediately following the play session, the home visitor will review the video recording with each parent separately to provide positive feedback on parental behaviors that promotes contingent interaction and identification of infant cues. At the end of the visit, standard public health handouts on infant sleep will be provided to both parents.
BACKGROUND: Chondroitin sulfate proteoglycan 4 pseudogene 12 (CSPG4P12) has been implicated in the pathogenesis of various cancers. This study aimed to evaluate the association of the CSPG4P12 polymorphism with esophageal squamous cell carcinoma (ESCA) risk and to explore the biological impact of CSPG4P12 expression on ESCA cell behavior.
METHODS: A case-control study was conducted involving 480 ESCA patients and 480 healthy controls to assess the association between the rs8040855 polymorphism and ESCA risk. The CSPG4P12 rs8040855 genotype was identified using the TaqMan-MGB probe method. Logistic regression model was used to evaluate the association of CSPG4P12 SNP with the risk of ESCA by calculating the odds ratios (OR) and 95% confidence intervals (95%CI ). The effects of CSPG4P12 overexpression on cell proliferation, migration, and invasion were examined in ESCA cell lines. Co-expressed genes were identified via the CBioportal database, with pathway enrichment analyzed using SangerBox. The binding score of CSPG4P12 to P53 was calculated using RNA protein interaction prediction (RPISeq). Additionally, Western Blot analysis was performed to investigate the impact of CSPG4P12 overexpression on the P53/PI3K/AKT signaling pathway.
RESULTS: The presence of at least one rs8040855 G allele was associated with a reduced susceptibility to ESCA compared to the CC genotype (OR = 0.51, 95%CI = 0.28-0.93, P = 0.03). Stratification analysis revealed that the CSPG4P12 rs8040855 C allele significantly decreased the risk of ESCA among younger individuals (≤ 57 years) and non-drinkers (OR = 0.31, 95%CI = 0.12-0.77, P = 0.01; OR = 0.42, 95%CI=0.20-0.87, P = 0.02, respectively). CSPG4P12 expression was found to be downregulated in ESCA tissues compared to adjacent normal tissues. Overexpression of CSPG4P12 in ESCA cells inhibited their proliferation, migration, and invasion capabilities. Furthermore, Western Blot analysis indicated that CSPG4P12 overexpression led to a reduction in PI3K and p-AKT protein expression levels. P53 silencing rescues the inhibitory effect of CSPG4P12 on p-AKT.
CONCLUSION: The CSPG4P12 rs8040855 variant is associated with reduced ESCA risk and the overexpression of CSPG4P12 inhibited the migration and invasion of ESCA cells by P53/PI3K/AKT pathway. These findings suggest that CSPG4P12 may serve as a novel biomarker for ESCA susceptibility and a potential target for therapeutic intervention.
The intervention group will be given an inspiratory muscle training device that will be regulated at 70% of their Maximum Inspiratory Pressure. This load is able to induce improvements in their musculature.
Hepatic Impairment: No pharmacokinetic studies were conducted with diazepam rectal gel in hepatically impaired subjects. Literature review indicates that following administration of 0.1 to 0.15 mg/kg of diazepam intravenously, the half-life of diazepam was prolonged by two to five-fold in subjects with alcoholic cirrhosis (n=24) compared to age-matched control subjects (n=37) with a corresponding decrease in clearance by half: however, the exact degree of hepatic impairment in these subjects was not characterized in this literature (see PRECAUTIONS).

Renal Impairment: The pharmacokinetics of diazepam have not been studied in renally impaired subjects (see PRECAUTIONS).

Pediatrics: No pharmacokinetic studies were conducted with diazepam rectal gel in the pediatric population. However, literature review indicates that following IV administration (0.33 mg/kg), diazepam has a longer half-life in neonates (birth up to one month; approximately 50-95 hours) and infants (one month up to two years; about 40-50 hours), whereas it has a shorter half-life in children (two to 12 years; approximately 15-21 hours) and adolescents (12 to 16 years; about 18-20 hours) (see PRECAUTIONS).

Elderly: A study of single dose IV administration of diazepam (0.1 mg/kg) indicates that the elimination half-life of diazepam increases linearly with age, ranging from about 15 hours at 18 years (healthy young adults) to about 100 hours at 95 years (healthy elderly) with a corresponding decrease in clearance of free diazepam (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).

Effect of Gender, Race, and Cigarette Smoking: No targeted pharmacokinetic studies have been conducted to evaluate the effect of gender, race, and cigarette smoking on the pharmacokinetics of diazepam. However, covariate analysis of a population of treated patients following administration of diazepam rectal gel, indicated that neither gender nor cigarette smoking had any effect on the pharmacokinetics of diazepam.
Subjects will be randomized into two groups, an active group and control group. For the first 30 days, the active group will follow the movement/breath program and the controls will be instructed not to change their lifestyle (no change in diet, and no change in exercise / physical activities). The technicians taking measurements will be blinded as to which participants are actives vs controls. The following 30 days' intervention will consist of continuing the Phase I interventions combined with implementing the behavior change strategies on 2 to 3 habit changes self-selected from a list of 30 top "bad habits" that contribute to weight gain and undermine one's ability to lose weight with the control group again not changing any lifestyle activities. Measurements: Measurements will be taken at the start (baseline), 10 days, 30 days, and 60 days of intervention with the measurement days scheduled to evaluate people completing 10 full days of the program, 30 full days, and 60 full days respectively. Measurements taken at each interval to include weight, body composition (lean mass \& fat percentages), anthropometric measurements (umbilicus, hips, right thigh, right upper arm), pO2, resting heart rate, HRV, blood pressure, pulmonary health (i.e., O2 max, spirometry), hunger, sleep, and depression rating (by self-assessment survey scale). Serum chemistry for basic metabolic panel, inflammatory markers, and lipids, hematology for oxygen carrying capacity and gross immune response, Human Growth Factor production via ELISA quantification, imaging ultrasound to measure subcutaneous fat thickness at the areas of girth measurements, DEXA for overall and targeted areas body composition, and resting metabolic rate via oxygen plethysmograph.
In radiation therapy, high-energy radiation beams treat tumors by damaging cancer cells. Treatment plans are designed with the goal of limiting exposure to adjacent healthy tissues. Commonly used radiation beams demonstrate the "skin-sparing effect" which means that the radiation dose builds up after the beam enters the skin and thus the maximum dose is reached at some depth beneath the skin. For many tumors, this spares the skin from unnecessary exposure while ensuring cancer cells beneath the skin receive the maximum dose. For cancers that lie at or just below the skin surface, however, it is desirable for the maximum dose be present at the skin surface. In such cases, a bolus (material with properties similar to tissue) is used to mimic tissue and is placed above the skin. Dose build up occurs within the bolus, thus allowing the maximum dose to be reached at the skin surface. Aside from the treatment of superficial tumors, boluses have recently been used for modulated electron radiation therapy (MERT). For MERT, the bolus thickness is varied so that the dose at a specific depth can be varied at different locations within the tissue. With this technique, the bolus is customized for a patient's specific anatomy and thus radiation exposure to healthy tissue is minimized.

Boluses are typically made from moldable materials such as paraffin wax or superflab. Conventional bolus preparation has its disadvantages; the patient is required to be present, it can be time intensive and it is dependent on the skill of the fabricator. Furthermore, the degree of conformity to the patient's skin is limited and, as a result, there can be significant air gaps between the bolus and the patient's skin. Such air gaps have been shown to create significant reduction in the surface dose.

The goal of the present study is to improve the current process of bolus preparation by creating customized boluses with 3D printing. Customized boluses can be designed in Varian eclipse software and then imported into 3D modeling software such as 3D Slicer. The 3D model can then be converted into STL (Stereolithography) format which can be interpreted by the 3D printer software. Several preliminary studies have reported success in creating such boluses. One study reported good fit without air gaps (Kim) in their 3D printed bolus. Additionally, several studies modeled tissue dose distributions for 3D printed boluses and found results were similar to those obtained for conventional boluses.

For the current study, the Investigators will enroll participants who require boluses as part of their treatment plan. Both a conventional and 3D bolus will be fabricated for each participant. Computer simulation of dose distributions will be used to compare dosimetric parameters. Additionally, air gaps for both boluses will be measured. For each participant, the bolus that results in a more optimized dose distribution will be used for the participant's actual treatment. Conducting the study will necessitate each enrolled participant to undergo an additional CT scan to simulate treatment with the 3D printed bolus.
Individuals with autism possess employable and valuable strengths and abilities. Unfortunately, despite these strengths, individuals with autism experience challenges in obtaining and maintaining employment. Traditionally, the majority of interventions designed for autism (including those focused on employment) focus on remediating deficits, without harnessing the strengths of those with autism. This deficit-based approach (i.e. to fix what is deficient in a person with autism) has triggered increasing criticism and dissatisfaction from the autism community. A growing shift toward strength-based training tools represent a holistic approach to treatment of autistic individuals by acknowledging and using their strengths to improve outcomes. To date, no strength-based employment programs have been examined in individuals with autism. Thus, in the current project, the investigators aim to develop and test a strength-based employment program. At Kessler Foundation, the investigators have developed a strength-based training tool: Kessler Foundation Strength Identification and Expression (KF-STRIDE®) which targets job interview skills by teaching individuals with autism to identify and express their personal strengths to a future employer. In the current proposal, the investigators aim to adapt this program to specifically target job maintenance skills.
FIELD: organic chemistry, biochemistry. SUBSTANCE: invention relates to novel derivatives of (tetrahydro-1-oxido-thiopyrane-4-yl)phenyloxazolidinone of the general formula (I)   where R 1  means methyl, ethyl, cyclopropyl, dichloromethyl group; R 2  and R 3  are similar or different and mean hydrogen or fluorine atom, or their pharmaceutically acceptable salts. Invention relates also to novel derivatives of (tetrahydro-1,1-oxido-thiopyrane-4-yl)phenyloxazo- lidinone of the general formula (II)   where R 2  and R 3  are similar or different and mean hydrogen or fluorine atom; R 4  means ethyl or dichloromethyl group, or to their pharmaceutically acceptable salts. Invention relates to method for testing derivatives of oxazolidinone of the formula (I) or (II) that can show inhibitory effect on monoamine oxidase activity involving the following steps: a) incubation of potential inhibitor with monoamine oxidase in buffer solution with pH value from about 7.0 to 7.5; b) addition of 1-methyl-4-(1-methyl-2-pyrryl)-1,2,3,6-tetrahydropyridine to the above indicated solution; and c) determination of inhibitory effect of the above indicated oxazolidinone on monoamine oxidase activity. Invention provides preparing compounds exhibiting inhibitory activity on monoamine oxidase activity. EFFECT: improved testing method, valuable biochemical properties. 21 cl, 1 tbl, 10 ex
Background: COVID-19 left consequences in different organs from months to years requiring different types of rehabilitation. In fact, a severe loss in the lung function, and in the respiratory and peripheral muscle strength is commonly observed in post-COVID-19 patients. Objectives: Thus, the present study investigated whether 30 days of supplementation with a nutritional blend (ImmuneRecov®; composition: whey protein concentrate, astaxanthin, creatine, selenium, vitamin C, glutamic acid, tryptophan, magnesium) would help to minimize the respiratory (lung function) and muscular (respiratory and peripheral muscles) sequelae in post-COVID-19 patients. Design: This is a non-controlled open label prospective clinical study. Methods: Fifty-eight post-COVID-19 patients were recruited and twenty-four accepted to take the nutritional blend, while twenty-four did not accept but required to participate in the evaluations and 10 refused to participate. So, the patients were evaluated before the 14th day after hospital discharge and after 30 days of use of the nutritional blend or control (no supplementation).